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Summary Cerebral metastases of cutaneous melanoma carry a very poorprognosis. We report ourexperience of 31 patients who presented
with cerebral metastasis of cutaneous melanoma in a 5-year period between mid-1991 and mid-1996. Cerebral metastases were diagnosed
on computerized tomography (CT) scan after patients became symptomatic. The overall median survival in our series was 4 months.
Seventeen patients (55%) received treatment with radiotherapy and dexamethasone with resolution of their symptoms, although median
survival remained at 4 months. Six patients (19%) had surgery followed by whole brain radiotherapy, with median survival of 5 months. The
remaining eight patients received dexamethasone alone. Data from patients surviving less than 2 months and over 6 months suggest that the
poor prognostic factors are the presence of more than one cerebral metastasis and additional extracranial metastases.
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Cutaneous malignant melanoma is the third most common cause
of cerebral metastases after breast and lung (Zimm et al, 1981).
The prevalence of cerebral metastases in patients with metastatic
malignant melanoma, as detected by computerized tomography
(CT) and magnetic resonance (MR), has been reported at approxi-
mately 20% (Retsas, 1988).
Cerebral metastases from malignant melanoma carry a poor
prognosis. In untreated cases, median survival is only a few weeks
(Amer et al, 1978) rising to 3-4 months in treated cases (Gottlieb
et al, 1972; Amer et al, 1978; Carella et al, 1980; Zimm et al, 1981;
Retsas, 1988). Various therapeutic measures have been assessed
including chemotherapy with agents such as cisplatin (Feun et al,
1990), fotemustine (Merimsky et al, 1991), lomustine (Retsas,
1988) and a combination of dacarbazine and fotemustine
(Merimsky et al, 1992; Chang et al, 1994). Radiotherapy (Zimm et
al, 1981; Retsas, 1988) and surgery (Zimm et al, 1981; Brega et al,
1990) have also been evaluated. However, in general, the effect on
mortality with all modalities oftreatment has been disappointing.
We report the clinical features, management and outcome of all
patients presenting to the departments of Dermatology and
Oncology, University ofGlasgow, Western Infirmary, Glasgow, with
cerebral metastasis from malignant melanoma over a 5-year period.
METHODS
Thirty-one patients presenting between mid-1991 and mid-1996
with melanoma and cerebral metastasis confirmed by CT scan
were identified. Data obtained included age, sex, site and thickness
of primary tumour, time interval between primary tumour and
cerebral metastasis, distribution ofmetastases, treatment given and
outcome. Symptoms before CT scan and 1 month after diagnosis
were evaluated and recorded as follows; symptoms resolved,
remained static or worsened.
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Patients received either no treatment or a course ofradiotherapy
with or without surgery. Radiotherapy was given to the whole
brain with X-rays which were emitted by a linear accelerator using
an energy of 4-6 MV and a dose of 20 Gy in five equal fractions
over 5 consecutive days. Surgery involved a craniotomy and exci-
sion of the metastasis, followed by a course of radiotherapy as
above. All patients received oral dexamethasone at a starting dose
of 16 mg per day.
Patient response was evaluated by serial CT scan of the brain.
This was categorized using the following generally accepted
criteria: complete response - complete resolution of all cerebral
metastases lasting at least 2 months; partial response - at least
50% decrease in the size of cerebral metastases lasting for more
than 2 months; stable disease - less than 50% decrease in the size
ofcerebral metastases over a 2-month period; progressive disease
- increase in size or the development of new cerebral metastases;
non-evaluable - patients unable to be evaluated as serial CT scans
ofthe brain were not performed.
Statistical analysis was performed using the chi-squared test.
RESULTS
Thirty-one patients were identified, of whom 16 (52%) were men
and 15 (48%) women. The age of the patients ranged from the
third to the seventh decade.
The commonest site of the primary lesion was the limb (45%).
Eleven (36%) primary lesions occurred on the trunk and two (6%)
on the head and neck. In four (13%) cases, the site of the primary
was not known.
Twenty primary lesions (65%) were over 1.5 mm thick with
only four (13%) being less than 1.5 mm. In seven patients (22%),
the tumour thickness ofthe primary was not known. Four ofthese
seven patients presented with stage II disease and had unknown
primary sites. One patient with a previously documented primary
site presented with stage III disease and the two remaining cases
were referred from other centres with unknown tumour thickness.
No patients in our study responded completely, but one (3%)
patient had a partial response. Four (13%) patients had stable
disease and 13 (42%) had progressive disease. In 13 (42%) cases,
256Cerebral metastases ofcutaneous melanoma 257
Table 1 Symptoms and signs of patients presenting with cerebral metastases and their response following treatment
Symptoms and signs
Symptoms and signs Number Percentage (%) Treatment Number Resolved Static Worsened
Headache 17 34 XRTa 11 10 0 1
DeXb 6 3 1 2
Nausea 11 22 XRT 6 6 0 0
Dex 5 1 3 1
Seizure 10 20 XRT 8 7 0 1
Dex 2 1 1 0
Motor deficit 4 8 XRT 4 3 0 1
Dex 0 0 0 0
Changein 4 8 XRT 2 1 0 1
mental status Dex 2 1 0 1
Dysphasia 2 4 XRT 2 2 0 0
Dex 0 0 0 0
Not known 2 4 XRT 2
aXRT, radiotherapy and dexamethasone. bDex, dexamethasone alone.
Table 2 Management and survival data of 31 patients with cerebral metastases from malignant melanoma
Treatment Number of patients Percentage (%) Median survival (months) Range (months)
Radiotherapy + dexamethasone 15 49 3.0 1-14
Surgery, radiotherapy + dexamethasone 6 19 5.0 3-14
Radiotherapy (twice) + dexamethasone 2 6 8.5 8-9
Dexamethasone alone 8 26 3.5 1-8
Table 3 Characteristics and management of 18 patients with cerebral
metastases from malignant melanoma: a comparison between two survival
groups
Survival after diagnosis
Patient characteristics 1-2 months > 6 months
Number of patients 8 10
Sex
Male 3 5
Female 5 5
Age (years)
Median 38 44.5
Range 26-67 27-60
Site of primary
Limb 5 4
Trunk 1 3
Head/neck 0 1
Unknown 2 2
Breslow thickness (mm)
>3.5 3 4
1.5-3.49 2 3
<1.49 0 0
Unknown primary 3 3
Spread to brain (months)
Median 31 23.5
Range 4-64 11-77
Metastases
Brain only 1 6
Brain + other sites 7 4
Overall treatment
Surgery+radiotherapy 0 3
Radiotherapy 5 6
Dexamethasone alone 3 1
repeat CT scans were not performed and therefore the patients
could not be evaluated.
The median time for the primary melanoma to metastasize to
the brain was 26.5 months (range 2-120 months). One patient
presented with cerebral metastasis.
The median survival time after the development of cerebral
metastasis was 4 months (range 1-14 months). The patient who
had a partial response survived for 8 months.
The presenting symptoms of these patients are noted in Table 1
and show that most of them presented with headaches, nausea or
seizures. The majority of patients received radiotherapy and
dexamethasone with good relief of their symptoms. It can be seen
from the table that radiotherapy and dexamethasone appears to be
superior to dexamethasone alone in symptom resolution.
Thirteen (42%) patients were found to have only one cerebral
metastasis and had a median survival time of 5 months (range
1-14 months). Eighteen (58%) patients had two or more cerebral
metastases and their median survival was 3 months (range 1-9
months). This reduction in survival time with multiple cerebral
metastases did not reach statistical significance (P = 0.1).
Ten (32%) patients developed cerebral metastasis alone, while
21 (68%) patients also had metastatic disease at other sites. The
median survival time for patients presenting with cerebral metas-
tasis alone was 6.5 months (range 1-14 months), whereas those
with disease elsewhere had a median survival time of 3 months
(range 1-9 months). The shorter survival time in those with meta-
stases at multiple sites was significant (P = 0.03).
Management and survival ofpatients with cerebral metastasis is
outlined in Table 2. This shows that the majority of patients were
treated with one course of radiotherapy; two patients had two
courses of radiotherapy for disease at different sites and six
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Table 4 Number of cerebral metastases and management of 18 patients with cerebral metastases from malignant melanoma: a comparison between
two survival groups
Number of cerebral metastases and management of these patients Survival after diagnosis
1-2 months > 6 months
One cerebral metastasis only
Number of patients 2 6
Treatment
Surgery + radiotherapy 0 3
Radiotherapy 2 2
Dexamethasone alone 0 1
Multiple cerebral metastases
Number of patients 6 4
Treatment
Surgery+ radiotherapy 0 0
Radiotherapy 2 4
Dexamethasone alone 4 0
Total number of patients 8 10
patients were treated with a combination of surgery and radio-
therapy. The remaining eight patients received dexamethasone
alone. The median survival time for patients who received dexa-
methasone alone and patients who received one course of radio-
therapy was the same. Patients who received radiotherapy with or
without surgery did not survive any longer than patients who were
treated with dexamethasone alone (P = 0.25).
To look for prognostic factors, patients surviving less than 2
months were compared with those surviving over 6 months
(Tables 3 and 4). Patients in the poor prognosis group had
more metastases in extracranial sites and also multiple cerebral
metastases (Table 4).
DISCUSSION
Metastatic malignant melanoma continues to pose major manage-
ment problems, and this is particularly the case for central nervous
system metastases as there is no effective therapeutic measure. This
contrasts with treatment for metastases outside the central nervous
system, which has improved with response rates of up to 41%
reported with combination chemotherapy (Stables et al, 1992).
The central nervous system acts as a sanctuary site for metas-
tases. This may be because of the relatively impermeable
blood-brain barrier to chemotherapeutic agents, therefore
explaining the disappointing results with cisplatin, fotemustine,
lomustine and dacarbazine.
Unlike previous studies (Merimsky et al, 1992), the age and sex
differences in our study did not seem to alter the prognosis in cere-
bral metastasis of melanoma. The majority of patients presented
with primary melanoma over 1.5 mm thick. Five-year survival for
this group has been reported to be 72.6%, falling to 48% if thick-
ness was over 3.5 mm (MacKie et al, 1992). Like previous studies
(Amer et al, 1978; Merimsky et al, 1992; Stevens et al, 1992), the
site ofthe primary tumour was not significantly correlated with the
development of cerebral metastasis. The median time for primary
melanoma to metastasize to the brain was similar to that described
by Retsas (1988) and Merimsky et al (1992).
The overall median survival time for our series was 4 months,
which is similar to that reported in previous studies (Gottlieb et al,
1972; Amer et al, 1978; Carella et al, 1980; Zimm et al, 1981;
Retsas, 1988). Patients presenting with one cerebral metastasis
survived for a longer period oftime than patients with two or more
metastases. Although not statistically significant in our study, this
has been documented in previous studies (Zimm et al, 1981;
Stevens et al, 1992).
The majority ofpatients presented with metastases in more than
one site and had lower survival figures than patients with cerebral
metastasis only. This was statistically significant and confirms
previous studies (Zimm et al, 1981; Stevens et al, 1992).
Malignant melanoma is relatively radioresistant. Radiotherapy
used to treat central nervous system metastases has given
conflicting results; some showing an increase in survival
(Mastrangelo et al, 1985) and others showing no improvement in
survival (Carella et al, 1980; Byrne et al, 1983; Fernandez et al,
1984; Madajewicz et al, 1984). Our results show that the majority
of patients were treated with radiotherapy and dexamethasone but
showed no improvement in survival compared with patients who
received dexamethasone alone. However, both dexamethasone and
radiotherapy offer useful palliative approaches (Harmer, 1976).
Surgery has also been evaluated for the treatment of cerebral
metastases from melanoma. Some studies have shown promising
results with median survivals of 5-10 months, although in
most of these studies patients presented with solitary metastasis
(Madajewicz et al, 1984; Brega et al, 1990; Stevens et al, 1992).
Our study suggests an improved survival time, but the results did
not reach statistical significance.
One ofthe key questions in the treatment ofcerebral metastasis is
when to perform a CT scan ofthe brain. In our study the majority of
patients presented with symptoms and therefore the yield ofpositive
scans was high. This is confirmed by previous studies which show
that the yield of true positive scans is high in patients with symp-
toms and low in asymptomatic cases (Buzaid et al, 1995).
From the data on patients surviving for less than 2 months and
for more than 6 months (Tables 3 and 4), it seems that the poor
prognostic factors are the presence of more than one cerebral
metastasis and disease in multiple sites, including the brain.
As radiotherapy did not prolong survival in our study, we
conclude that patients should be investigated with a CT head scan
only ifthey are symptomatic. All patients with cerebral metastasis
should be commenced on dexamethasone at a starting, divided,
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dose of 16 mg per day and radiotherapy should be considered if
symptoms persist. For solitary cerebral metastasis with no
evidence ofextracranial disease, surgery and post-operative radio-
therapy should be considered as there is some evidence of
improved survival. For multiple cerebral metastases and metas-
tases in extracranial sites the prognosis remains poor.
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